Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | TPH1 | P17752 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | XBP1 | P17861 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10166441 | 0.90 | HCRTR2 (0.58) | TP53HCRTR2HDAC1ACHEHCRTR1 | |
| SCHEMBL10166866 | 0.90 | HCRTR2 (0.58) | TP53HCRTR2HDAC1NAMPTACHE | |
| SCHEMBL10166151 | 0.89 | HCRTR2 (0.57) | TP53HCRTR2HDAC1ACHEHCRTR1 | |
| SCHEMBL10165791 | 0.87 | TP53 (0.51) | TP53HCRTR2HDAC1NAMPTACHE | |
| SCHEMBL667392 | 0.82 | KCNK3 (0.41) | KCNK3 | |
| SCHEMBL667539 | 0.76 | HCRTR2 (0.78) | TP53HCRTR2HDAC1HCRTR1 | |
| SCHEMBL667759 | 0.75 | HCRTR2 (0.80) | TP53HCRTR2HDAC1HCRTR1 | |
| SCHEMBL667753 | 0.73 | HCRTR2 (0.41) | HCRTR2KCNK3HCRTR1 | |
| SCHEMBL668036 | 0.72 | HCRTR2 (0.42) | HCRTR2 | |
| SCHEMBL666604 | 0.72 | HCRTR2 (0.40) | HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046289-A1 | Pyridazine Carboxamide Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046289-A1 | Pyridazine Carboxamide Orexin Receptor Antagonists | HCRTR2, HCRTR1, NPY5R | TP53 4884/4885HCRTR2 1/4885HDAC1 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.